Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 3
2018 2
2019 1
2020 1
2021 2
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
SLCO4A1 expression is associated with activated inflammatory pathways in high-grade serous ovarian cancer.
Koller S, Kendler J, Karacs J, Wolf A, Kreuzinger C, Von Der Decken I, Mungenast F, Mechtcheriakova D, Schreiner W, Gleiss A, Jäger W, Cacsire Castillo-Tong D, Thalhammer T. Koller S, et al. Among authors: kreuzinger c. Front Pharmacol. 2022 Aug 29;13:946348. doi: 10.3389/fphar.2022.946348. eCollection 2022. Front Pharmacol. 2022. PMID: 36105223 Free PMC article.
AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication.
Monjé N, Dragomir MP, Sinn BV, Hoffmann I, Makhmut A, Simon T, Kunze CA, Ihlow J, Schmitt WD, Pohl J, Piwonski I, Marchenko S, Keunecke C, Calina TG, Tiso F, Kulbe H, Kreuzinger C, Cacsire Castillo-Tong D, Sehouli J, Braicu EI, Denkert C, Darb-Esfahani S, Kübler K, Capper D, Coscia F, Morkel M, Horst D, Sers C, Taube ET. Monjé N, et al. Among authors: kreuzinger c. Br J Cancer. 2024 May;130(8):1249-1260. doi: 10.1038/s41416-023-02550-1. Epub 2024 Feb 9. Br J Cancer. 2024. PMID: 38361045 Free PMC article.
Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.
Stanske M, Wienert S, Castillo-Tong DC, Kreuzinger C, Vergote I, Lambrechts S, Gabra H, Gourley C, Ganapathi RN, Kolaschinski I, Budczies J, Sehouli J, Ruscito I, Denkert C, Kulbe H, Schmitt W, Jöhrens K, Braicu I, Darb-Esfahani S. Stanske M, et al. Among authors: kreuzinger c. Neoplasia. 2018 Mar;20(3):280-288. doi: 10.1016/j.neo.2018.01.007. Epub 2018 Feb 22. Neoplasia. 2018. PMID: 29466768 Free PMC article.
Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer.
Westergaard MCW, Milne K, Pedersen M, Hasselager T, Olsen LR, Anglesio MS, Borch TH, Kennedy M, Briggs G, Ledoux S, Kreuzinger C, Decken IV, Donia M, Castillo-Tong DC, Nelson BH, Svane IM. Westergaard MCW, et al. Among authors: kreuzinger c. Cancers (Basel). 2020 Dec 18;12(12):3828. doi: 10.3390/cancers12123828. Cancers (Basel). 2020. PMID: 33352957 Free PMC article.
Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients.
Bartl T, Karacs J, Kreuzinger C, Pfaffinger S, Kendler J, Ciocsirescu C, Wolf A, Reinthaller A, Meyer E, Brandstetter M, Postl M, Langthaler E, Braicu E, Vergote I, Cunnea P, Gourley C, Schmitt WD, Cacsire Castillo-Tong D, Christoph G. Bartl T, et al. Among authors: kreuzinger c. Cancers (Basel). 2021 Mar 3;13(5):1076. doi: 10.3390/cancers13051076. Cancers (Basel). 2021. PMID: 33802395 Free PMC article.
A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.
Kreuzinger C, Geroldinger A, Smeets D, Braicu EI, Sehouli J, Koller J, Wolf A, Darb-Esfahani S, Joehrens K, Vergote I, Vanderstichele A, Boeckx B, Lambrechts D, Gabra H, Wisman GBA, Trillsch F, Heinze G, Horvat R, Polterauer S, Berns E, Theillet C, Cacsire Castillo-Tong D. Kreuzinger C, et al. Clin Cancer Res. 2017 Dec 15;23(24):7621-7632. doi: 10.1158/1078-0432.CCR-17-1159. Epub 2017 Oct 2. Clin Cancer Res. 2017. PMID: 28972047 Free article.
Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.
Kreuzinger C, von der Decken I, Wolf A, Gamperl M, Koller J, Karacs J, Pfaffinger S, Bartl T, Reinthaller A, Grimm C, Singer CF, Braicu EI, Cunnea P, Gourley C, Smeets D, Boeckx B, Lambrechts D, Perco P, Horvat R, Berns EMJJ, Cacsire Castillo-Tong D. Kreuzinger C, et al. Cancer Lett. 2019 Sep 10;459:1-12. doi: 10.1016/j.canlet.2019.05.032. Epub 2019 May 28. Cancer Lett. 2019. PMID: 31150822
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, Trillsch F, Mustea A, Kreuzinger C, Gourley C, Gabra H, Taube ET, Dorigo O, Horst D, Keunecke C, Baum J, Angelotti T, Sehouli J, Braicu EI. Glajzer J, et al. Among authors: kreuzinger c. Ann Surg Oncol. 2023 Jan;30(1):35-45. doi: 10.1245/s10434-022-12459-3. Epub 2022 Sep 9. Ann Surg Oncol. 2023. PMID: 36085390 Free PMC article.
13 results